GLP-1 receptor agonist
This page covers all GLP-1 receptor agonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting GLP-1R, Glucagon-like peptide 1 receptor, GLP-1 receptor.
Targets
GLP-1R · Glucagon-like peptide 1 receptor · GLP-1 receptor · GLP-1R (glucagon-like peptide-1 receptor) · GLP-1R (GLP-1 receptor)
Marketed (30)
- Receptor Agonists (GLP1RA) · Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - Victoza (liraglutide) · Zealand University Hospital · Diabetes
Victoza activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - GLP1 receptor agonist · Weill Medical College of Cornell University · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - exenatide (Byetta) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - liraglutide monotherapy · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to elevated blood glucose. - Albugon · GSK · Metabolic
- semaglutide or tirzepatide · Mayo Clinic · Metabolic
Semaglutide and tirzepatide are GLP-1 receptor agonists that enhance glucose-dependent insulin secretion and reduce glucagon secretion, leading to improved glycemic control and weight loss. - sub cutaneous liraglutide · Yaounde Central Hospital · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying. - Exenatide once weekly (QW) · Eli Lilly and Company · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - Semaglutide Pen Injector · University of Pennsylvania · Diabetes, Obesity
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - Exenatide twice daily (BID) · Eli Lilly and Company · Diabetes
Exenatide activates GLP-1 receptors on pancreatic beta cells to stimulate insulin secretion in response to elevated blood glucose. - GLP-1 receptor agonist · Brigham and Women's Hospital · Diabetes
GLP-1 receptor agonists activate glucagon-like peptide-1 receptors to stimulate insulin secretion, suppress glucagon release, and slow gastric emptying, thereby lowering blood glucose levels. - Liraglutide + Exercise training · University of Virginia · Diabetes
Liraglutide activates GLP-1 receptors to enhance insulin secretion and reduce appetite, while exercise training improves insulin sensitivity and cardiovascular fitness through physical conditioning. - Ozempic® · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Diabetes
Ozempic activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose levels in type 2 diabetes. - Semaglutide (Rybelsus®) · Instituto Mexicano del Seguro Social · Diabetes
Semaglutide activates GLP-1 receptors to increase insulin secretion, decrease glucagon release, and slow gastric emptying, thereby lowering blood glucose and promoting weight loss. - Lixisenatide (AVE0010) · Sanofi · Diabetes
Lixisenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Semaglutide Treatment · University Health Network, Toronto · Endocrinology
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - NovoHelisen Depot · Wroclaw Medical University · Diabetes
NovoHelisen Depot is a long-acting formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist. - dulaglutide injection · First Affiliated Hospital of Zhejiang University · Diabetes
Dulaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce glucagon release in response to elevated blood glucose. - Liraglutide+standard-of-care treatment · Second Affiliated Hospital, School of Medicine, Zhejiang University · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion, suppress glucagon, and slow gastric emptying, used here in combination with standard diabetes care. - Byetta (Exenatide) · Beijing Chao Yang Hospital · Diabetes
Exenatide mimics glucagon-like peptide-1 (GLP-1) to stimulate insulin secretion in response to blood glucose elevation and suppress glucagon release. - Liraglutide injection · Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca · Diabetes; Obesity
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby reducing blood glucose and promoting weight loss. - GLP-1 RAs · Shanghai 10th People's Hospital · Endocrinology / Diabetes
GLP-1 receptor agonists activate the glucagon-like peptide-1 receptor to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby reducing blood glucose levels. - Liraglutide Pen Injector [Saxenda] · University College, London · Endocrinology / Obesity
Liraglutide activates GLP-1 receptors in the brain and pancreas to reduce appetite, increase satiety, and promote weight loss. - Liraglutide Pen Injector [Victoza] · Imperial College London · Diabetes
Liraglutide activates GLP-1 receptors to stimulate insulin secretion, suppress glucagon, and slow gastric emptying, thereby lowering blood glucose levels. - Danuglipron · Pfizer · Metabolic
Danuglipron is a small-molecule GLP-1 receptor agonist. - Dulaglutide Pen · Eli Lilly and Company · Diabetes
Dulaglutide activates GLP-1 receptors on pancreatic beta cells to increase insulin secretion and suppress glucagon in response to elevated blood glucose. - Benaglutide Injection · The Affiliated Hospital of Qingdao University · Diabetes
Benaglutide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Semaglutide Pen Injector [Ozempic] · University of Nottingham · Diabetes
Semaglutide activates GLP-1 receptors to increase insulin secretion, slow gastric emptying, and reduce appetite, thereby lowering blood glucose and body weight. - Semaglutide Injectable Product · Neurogastrx, Inc. · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Phase 3 pipeline (92)
- Albiglutide liquid auto-injector · GlaxoSmithKline · Diabetes
Albiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and lower blood glucose in patients with type 2 diabetes. - HPP2104-1 · Hanmi Pharmaceutical Company Limited · Diabetes
HPP2104-1 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. - DWP16001 · Daewoong Pharmaceutical Co. LTD. · Endocrinology / Diabetes
DWP16001 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Exenatide infusion · Amsterdam UMC, location VUmc · Diabetes
Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion and reduce blood glucose in response to meals. - exenatide, long acting release · AstraZeneca · Diabetes
Exenatide, long acting release, works by mimicking the action of a natural hormone in the body to help lower blood sugar levels. - Exenatide Once Weekly · AstraZeneca · Diabetes
Exenatide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying in response to blood glucose levels. - HPP2103-2 · Hanmi Pharmaceutical Company Limited · Diabetes
HPP2103-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. - Sevre-Long™ · Mundipharma Medical Company · Diabetes
Sevre-Long™ is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to regulate glucose metabolism. - Lyophilized albiglutide DCC pen injector · GlaxoSmithKline · Diabetes
Albiglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the incretin hormone GLP-1 to lower blood glucose levels. - Venglustat GZ402671 · Sanofi · Diabetes
Venglustat is a selective and reversible inhibitor of glucosylceramidase. - HCP1302 · Hanmi Pharmaceutical Company Limited · Diabetes
HCP1302 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - PEX168(200µg) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · Diabetes
PEX168 is a long-acting GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Umkamin(Active Comparator) · Hanlim Pharm. Co., Ltd. · Diabetes
Umkamin is a glucagon-like peptide-1 (GLP-1) receptor agonist. - Placebo II (Semaglutide) · Novo Nordisk A/S · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. - placebo to match albiglutide · GlaxoSmithKline · Diabetes
This drug is a placebo that matches the mechanism of albiglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. - Exendin-4 Fc fusion protein injection · Beijing Dongfang Biotech Co., Ltd. · Diabetes
Exendin-4 Fc fusion protein activates GLP-1 receptors to stimulate insulin secretion and suppress glucagon in response to elevated blood glucose. - NNC0365-3769 (Mim8) · Novo Nordisk A/S · Diabetes
Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist. - HPP2004 · Hanmi Pharmaceutical Company Limited · Diabetes
HPP2004 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Ecnoglutide High Dosage · Hangzhou Sciwind Biosciences Co., Ltd. · Diabetes
Ecnoglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve glycemic control. - HCP1701 · Hanmi Pharmaceutical Company Limited · Endocrinology / Diabetes
HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - JKN2401 Injection · Joincare Pharmaceutical Group Industry Co., Ltd · Endocrinology / Diabetes
JKN2401 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control. - Noiiglutide Injection · Jiangsu HengRui Medicine Co., Ltd. · Diabetes
Noiiglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to enhance insulin secretion and improve blood glucose control. - Semaglutide J · Novo Nordisk A/S · Diabetes, Obesity
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying. - HGP2102-2 · Hanmi Pharmaceutical Company Limited · Endocrinology / Diabetes
HGP2102-2 is a long-acting GLP-1 receptor agonist designed to improve glycemic control in diabetes by enhancing insulin secretion and reducing glucagon release. - SHR8554 Injection · Jiangsu HengRui Medicine Co., Ltd. · Diabetes
SHR8554 Injection is a glucagon-like peptide-1 (GLP-1) receptor agonist. - HGP1911 · Hanmi Pharmaceutical Company Limited · Endocrinology
HGP1911 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - GB242 · Genor Biopharma Co., Ltd. · Diabetes
GB242 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - Tyroserleutide for injection · Shenzhen Kangzhe Pharmaceutical Co., Ltd. · Diabetes
Tyroserleutide for injection is a recombinant human proinsulin-derived peptide that mimics the action of incretin hormones to enhance glucose-dependent insulin secretion. - HGP1909 · Hanmi Pharmaceutical Company Limited · Diabetes
HGP1909 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - HCP1803-3 · Hanmi Pharmaceutical Company Limited · Diabetes
HCP1803-3 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - HGP1011 · Hanmi Pharmaceutical Company Limited · Endocrinology
HGP1011 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - Exenatide Microspheres for Injection · Xiangya Hospital of Central South University · Diabetes
Exenatide is a GLP-1 receptor agonist that stimulates insulin secretion and reduces glucagon in response to elevated blood glucose. - Drug: Semaglutide Administered SC · BrightGene Bio-Medical Technology Co., Ltd. · Diabetes, Obesity, Cardiovascular
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, suppress appetite, and promote weight loss. - HGP1705 · Hanmi Pharmaceutical Company Limited · Diabetes
HGP1705 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - HPP2202 · Hanmi Pharmaceutical Company Limited · Diabetes
HPP2202 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - semaglutide injection (HD1916) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Diabetes
Semaglutide injection works by mimicking the action of a natural hormone in the body called glucagon-like peptide-1 (GLP-1) to help lower blood sugar levels. - BYETTA treatment · Assistance Publique Hopitaux De Marseille · Diabetes
Byetta (exenatide) is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion in response to elevated blood glucose levels. - HGP1910 · Hanmi Pharmaceutical Company Limited · Endocrinology
HGP1910 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. - JK-1201I · JenKem Technology Co., Ltd. · Endocrinology/Metabolic Disease
JK-1201I is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. - Liraglutide Pen Injector · University of North Carolina, Chapel Hill · Diabetes
Liraglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to stimulate insulin secretion, suppress glucagon, and slow gastric emptying.
Phase 2 pipeline (6)
- Albiglutide weekly injection · GlaxoSmithKline · Diabetes
GLP-1 receptor agonist - GLP-1 analogs · Canadian Network for Observational Drug Effect Studies, CNODES · Diabetes
GLP-1 analogs mimic the action of the hormone glucagon-like peptide-1 to regulate blood sugar levels. - Efluelda® Pre-filled syringe · Sanofi · Diabetes
Efluelda is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. - Dulaglutide,QW · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Diabetes
GLP-1 receptor agonist - Cotadutide 600 micrograms · AstraZeneca · Diabetes
Cotadutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels. - GSK2798745 solution · GlaxoSmithKline · Diabetes
GSK2798745 solution is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Phase 1 pipeline (2)
- Albiglutide Lyophilized DCC Pen Injector · GlaxoSmithKline · Diabetes
GLP-1 receptor agonist - Arm 5- Tirzepatide · Lexaria Bioscience Corp. · Diabetes
GLP-1 receptor agonist